SECURITIESFORM AND EXCHANGE COMMISSION8-K

Item 2.02 Results of Operations and Financial Condition.

IfItem an9.01 emergingFinancial growthStatements company,and indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange ActExhibits. ☐

UNITED ~~STATES~~STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549

~~WASHINGTON,~~CURRENT ~~D.C. 20549~~REPORT

~~FORM~~Pursuant ~~8-K~~to Section 13 or 15(d) of the Securities Exchange Act of 1934

~~CURRENT~~Date ~~REPORT~~of Report (Date of earliest event reported): March 12, 2026

~~Pursuant~~CANDEL toTHERAPEUTICS, ~~Section 13 or 15(d)~~INC.

(Exact name of ~~the~~Registrant ~~Securities~~as ~~Exchange~~Specified ~~Act~~in ofIts ~~1934~~Charter)

Date of Report (Date of earliest event reported): February 19, 2026


Delaware	001-40629	52-2214851
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

117 Kendrick St Suite 450
Needham, Massachusetts		02494
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s ~~CANDEL~~Telephone ~~THERAPEUTICS~~Number, ~~INC.~~Including Area Code: (617) 916-5445

~~(Exact~~Not ~~name of Registrant as Specified in Its Charter)~~Applicable

Delaware		001-40629		52-2214851
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

(Former Name or Former Address, if Changed Since Last Report)

117 Kendrick St., Suite 450 Needham, MA		02494
(Address of Principal Executive Offices)		(Zip Code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

~~Registrant’s~~☐Written ~~Telephone~~communications ~~Number,~~pursuant ~~Including~~to ~~Area~~Rule ~~Code:~~425 under the Securities Act (~~617)~~17 ~~916-5445~~CFR 230.425)

~~Not~~☐Soliciting ~~Applicable~~material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

~~(Former~~☐Pre-commencement ~~Name~~communications orpursuant ~~Former~~to ~~Address,~~Rule if14d-2(b) ~~Changed~~under ~~Since~~the ~~Last~~Exchange ~~Report~~Act (17 CFR 240.14d-2(b))

~~Check the appropriate box below if the Form 8~~☐Pre-Kcommencement ~~filing~~communications ispursuant ~~intended~~ to ~~simultaneously~~Rule ~~satisfy~~13e-4(c) ~~the~~under ~~filing obligation of~~ the ~~registrant~~Exchange ~~under~~Act ~~any~~(17 ofCFR ~~the following provisions:~~240.13e-4(c))

☐Securities ~~Written~~registered ~~communications~~ pursuant to ~~Rule~~Section ~~425~~12(b) ~~under~~of the ~~Securities~~ Act ~~(17 CFR 230.425)~~:

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.01 par value per share	CADL	The Nasdaq Global Market

☐Indicate ~~Pre-commencement~~by ~~communications~~check ~~pursuant~~mark towhether the registrant is an emerging growth company as defined in Rule ~~14d-2~~405 of the Securities Act of 1933 (b§ 230.405 of this chapter) ~~under~~or Rule 12b-2 of the Securities Exchange Act ~~(17~~of ~~CFR~~1934 (§ 240.~~14d~~12b-2(b of this chapter)).

☐Emerging ~~Pre-commencement~~growth ~~communications~~company ~~pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))~~☒

~~Securities~~If ~~registered~~an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 12 13(ba) of the Exchange Act:. ☐

Title of each class		TradingSymbol(s)		Name of each exchangeon which registered
Common Stock, $0.01 par value per share		CADL		The Nasdaq Global Market

~~Indicate~~On byMarch ~~check~~12, ~~mark~~2026, ~~whether~~Candel ~~the~~Therapeutics, ~~registrant~~Inc. isannounced anits ~~emerging~~financial ~~growth~~results ~~company~~for asthe ~~defined~~quarter inand ~~Rule~~year ~~405~~ended ofDecember ~~the~~31, ~~Securities~~2025. ~~Act~~The offull ~~1933~~text ~~(§ 230.405~~ of ~~this~~the ~~chapter)~~press orrelease ~~Rule~~issued ~~12b-2~~in ofconnection with the ~~Securities~~announcement ~~Exchange~~is ~~Act~~furnished ofas ~~1934~~Exhibit ~~(§ 240~~99.~~12b-2~~1 ofto this ~~chapter)~~Current Report on Form 8-K.

~~Emerging~~The ~~growth~~information ~~company ☒~~in this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is furnished herewith and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Candel Therapeutics, Inc.

Date: February 23, 2026

/s/ Paul Peter Tak

Paul Peter Tak, M.D., Ph.D., FMedSci

President and Chief Executive Officer

~~Item~~(d) ~~1.01. Entry into a Material Definitive Agreement~~Exhibits

On February 19, 2026, Candel Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Citigroup Global Markets Inc., Cantor Fitzgerald & Co., and Stifel, Nicolaus & Company, Incorporated, as representatives (the “Representatives”) of the underwriters named therein (the “Underwriters”), pursuant to which the Company agreed to issue and sell an aggregate of 18,348,624 shares (the “Firm Shares”) of its common stock, par value $0.01 per share (the “Common Stock”), at a price to the public of $5.45 per share (the “Offering”). Pursuant to the Underwriting Agreement, the Company granted the underwriters a 30-day option to purchase up to an additional 2,752,293 shares of its Common Stock (the “Optional Shares”, and together with the Firm Shares, the “Shares”) at the public offering price, less underwriting discounts and commissions. The Underwriting Agreement contains customary representations and warranties, conditions to closing, market standoff provisions, termination provisions and indemnification obligations, including for liabilities under the Securities Act of 1933, as amended (the “Securities Act”). The Offering was made pursuant to a shelf registration statement on Form S-3 (File No. 333-289595) that was initially filed by the Company with the Securities and Exchange Commission (the “SEC”) on August 14, 2025, and declared effective by the SEC on August 22, 2025, and a related prospectus supplement.


Exhibit Number		Description
99.1		Press Release dated March 12, 2026
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

The Company estimates that the net proceeds of this offering, after deducting underwriting discounts and commissions and estimated offering expenses, will be approximately $93.5 million (or approximately $107.6 million if the underwriters exercise their option to purchase additional shares in full). The Company intends to use the net proceeds from the offering to complete critical launch readiness, medical affairs, pre-commercialization, and commercial activities for CAN-2409 in early localized prostate cancer, ongoing development costs related to the phase 3 trial for CAN-2409 in non-small cell lung cancer, and for general corporate purposes. The Company expects the Offering to close on or about February 23, 2026, subject to the satisfaction of customary closing conditions. SIGNATURES

~~The~~Pursuant ~~Underwriting Agreement is filed as Exhibit 1.1~~ to ~~this Current Report on Form 8-K and is incorporated herein by reference, and~~ the ~~foregoing~~requirements ~~description~~ of the ~~terms~~Securities ofExchange ~~the~~Act ~~Underwriting Agreement is qualified in its entirety by reference to such exhibit. A copy~~ of 1934, the ~~opinion~~registrant ofhas ~~Goodwin~~duly ~~Procter~~caused ~~LLP,~~this ~~relating~~report to ~~the~~be ~~validity~~signed ofon ~~the~~its ~~Shares~~behalf inby ~~connection with~~ the ~~Offering,~~undersigned ishereunto ~~filed~~duly ~~as Exhibit 5~~authorized.~~1 to this Current Report on Form 8-K.~~

Item 8.01. Other Events.


			Candel Therapeutics, Inc.

Date:	March 12, 2026	By:	/s/ Paul Peter Tak
			Paul Peter Tak, M.D., Ph.D., FMedSci President and Chief Executive Officer

On February 19, 2026, the Company issued press releases announcing the launch and the pricing of the Offering. Copies of the press releases are filed as Exhibits 99.1 and 99.2 to this Current Report on Form 8-K and are incorporated herein by reference.

Assuming net proceeds of $93.5 million from the base Offering, and excluding any additional proceeds from the underwriters’ exercise of their option to purchase additional shares, the Company expects its cash and cash equivalents will enable the Company to fund its operating expenses and capital expenditure requirements into the first quarter of 2028. The Company has based its estimates on assumptions that may prove to be wrong, and the Company could use its available capital resources sooner than it currently expects.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits.

Exhibit No.		Description
1.1		Underwriting Agreement dated February 19, 2026.
5.1		Opinion of Goodwin Procter LLP.
23.1		Consent of Goodwin Procter LLP (contained in Exhibit 5.1).
99.1		Launch Press Release dated February 19, 2026.
99.2		Pricing Press Release dated February 19, 2026.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

Forward-Looking Statements

This Current Report on Form 8-K contains forward-looking statements that are based on the Company’s beliefs and assumptions and on information currently available to the Company on the date of this Current Report. These forward-looking statements involve substantial risks and uncertainties. Any statements in this Current Report on Form 8-K other than statements of historical fact, including statements about the Company’s future expectations, plans and prospects, constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Forward-looking statements include any statements about the Company’s strategy, operations and future expectations and plans and prospects for the Company, and any other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend”, “goal,” “may”, “might,” “plan,” “predict,” “project,” “seek,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions. Such forward-looking statements involve substantial risks and uncertainties that could cause the Company’s financial and operating results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements, including the factors discussed in the “Risk Factors” section contained in the quarterly and annual reports that the Company files with the Securities and Exchange Commission. Any forward-looking statements represent the Company’s views only as of the date of this Current Report on Form 8-K. The Company anticipates that subsequent events and developments may cause its views to change. While the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so except as required by law even if new information becomes available in the future.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Filing Compare · Candel Therapeutics, Inc.